www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
AS PER PRIOR POST, ADDING TO $ACOR (ACORDIA) SHORT AT $33.37
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
WOW! FDA AGREES WITH OUR LONGSTANDING ASSESSMENT OF FAMPRIDINE-SR , SHORT SELL $ACOR (ACORDIA) PER OUR PRIOR POST
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED
The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR's Fampridine-SR for improvement of walking in patients with multiple sclerosis .We have been negative on ACOR from the very beginning ...
CHECK OUR PERFORMANCE
